CliffBio
small molecule

RAPAFLO

SILODOSIN

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameRAPAFLO
Active ingredientSILODOSIN
Strength8MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2008
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RAPAFLO patent cliff — loss of exclusivity — | CliffBio